Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study

Saroglitazar, a dual peroxisome proliferator activated receptor α/γ agonist, approved for diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver disease (NAFLD). This prospective, observational, real-world study aimed to determine efficacy and safety of Saroglitaza...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sci Rep
Hauptverfasser: Goyal, Omesh, Nohria, Sahil, Goyal, Prerna, Kaur, Jaskirat, Sharma, Sarit, Sood, Ajit, Chhina, Rajoo Singh
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7713236/
https://ncbi.nlm.nih.gov/pubmed/33273703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-78342-x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge